These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17324475)

  • 1. Schizophrenia as a GSK-3 dysregulation disorder.
    Lovestone S; Killick R; Di Forti M; Murray R
    Trends Neurosci; 2007 Apr; 30(4):142-9. PubMed ID: 17324475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.
    Freyberg Z; Ferrando SJ; Javitch JA
    Am J Psychiatry; 2010 Apr; 167(4):388-96. PubMed ID: 19917593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Schizophrenia, neurodevelopment and glycogen synthase kinase-3].
    Nadri C; Kozlovsky N; Agam G
    Harefuah; 2003 Sep; 142(8-9):636-42, 644. PubMed ID: 14518171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK-3 and the neurodevelopmental hypothesis of schizophrenia.
    Kozlovsky N; Belmaker RH; Agam G
    Eur Neuropsychopharmacol; 2002 Feb; 12(1):13-25. PubMed ID: 11788236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An emerging role for Wnt and GSK3 signaling pathways in schizophrenia.
    Singh KK
    Clin Genet; 2013 Jun; 83(6):511-7. PubMed ID: 23379509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling.
    Sutton LP; Rushlow WJ
    Neuroscience; 2011 Dec; 199():116-24. PubMed ID: 22001305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of glycogen synthase kinase-3β in the pathogenesis of mental disorders].
    Ivanova SA; Losenkov IS; Bokhan NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):93-100. PubMed ID: 25075421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction?
    Manduca JD; Thériault RK; Perreault ML
    Pharmacol Res; 2020 Jul; 157():104819. PubMed ID: 32305493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-β activity.
    Benedetti F; Poletti S; Radaelli D; Bernasconi A; Cavallaro R; Falini A; Lorenzi C; Pirovano A; Dallaspezia S; Locatelli C; Scotti G; Smeraldi E
    Genes Brain Behav; 2010 Jun; 9(4):365-71. PubMed ID: 20113358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.
    Tang H; Shen N; Jin H; Liu D; Miao X; Zhu LQ
    Mol Neurobiol; 2013 Dec; 48(3):404-11. PubMed ID: 23440732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
    Amar S; Belmaker RH; Agam G
    Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos.
    Acevedo N; Wang X; Dunn RL; Smith GD
    Mol Reprod Dev; 2007 Feb; 74(2):178-88. PubMed ID: 16941690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.
    Cole AR
    FEBS J; 2013 Nov; 280(21):5213-27. PubMed ID: 23796137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment.
    Ferreira AS; Raposo NR; Sallet PC; Van de Bilt MT; Machado-Vieira R; Talib LL; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 2015 Mar; 265(2):167-70. PubMed ID: 24831601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activator or inhibitor? GSK-3 as a new drug target.
    Takahashi-Yanaga F
    Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focusing the spotlight on GSK-3 in aging.
    Zhou J; Force T
    Aging (Albany NY); 2013 Jun; 5(6):388-9. PubMed ID: 23804600
    [No Abstract]   [Full Text] [Related]  

  • 17. The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle.
    Ryves WJ; Harwood AJ
    Prog Cell Cycle Res; 2003; 5():489-95. PubMed ID: 14593744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic correlational analysis of glycogen synthase kinase-3 beta and prepulse inhibition in inbred mice.
    Amar S; Jones BC; Nadri C; Kozlovsky N; Belmaker RH; Agam G
    Genes Brain Behav; 2004 Jun; 3(3):178-80. PubMed ID: 15140013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum.
    Alimohamad H; Rajakumar N; Seah YH; Rushlow W
    Biol Psychiatry; 2005 Mar; 57(5):533-42. PubMed ID: 15737669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism.
    MacAulay K; Doble BW; Patel S; Hansotia T; Sinclair EM; Drucker DJ; Nagy A; Woodgett JR
    Cell Metab; 2007 Oct; 6(4):329-37. PubMed ID: 17908561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.